Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 ...

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price target of $183.00. The company’s s ...

Nanoscope Therapeutics Inc., a biotech company pioneering gene-agnostic therapies to restore vision in blind patients suffering from retinal degenerative diseases, today announced its participation in ...

IQVIA , a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...

Ionis Pharmaceuticals’ RNA-targeted drug Waylivra has been conditionally approved in Europe for the devastating ultra-rare disease Familial Chylomicronemia Syndrome (FCS).